Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer
- Equal contributors
1 State Key Laboratory of Oncology in South China, Guangzhou 510060, China
2 Department of Gastric & pancreatic Surgery, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China
3 Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China
4 Department of Pathology, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China
5 Department of Pathology, the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510060, China
BMC Cancer 2010, 10:536 doi:10.1186/1471-2407-10-536Published: 7 October 2010
The mammalian target of rapamycin (mTOR) plays a key role in cellular growth and homeostasis. The purpose of our present study is to investigate the expression of activated mTOR (p-mTOR) in gastric cancer patients, their prognostic significance and the inhibition effect of RAD001 on tumor growth and to determine whether targeted inhibition of mTOR could be a potential therapeutic strategy for gastric cancer.
The expression of p-mTOR was detected in specimens of 181 gastric cancers who underwent radical resection (R0) by immunohistochemistry. The correlation of p-mTOR expression to clinicopathologic features and survival of gastric cancer was studied. We also determined the inhibition effect of RAD001 on tumor growth using BGC823 and AGS human gastric cancer cell lines.
Immunostaining for p-mTOR was positive in 93 of 181 (51.4%) gastric cancers, closely correlated with lymph node status and pTNM stage. Patients with p-mTOR positive showed significantly shorter disease-free survival (DFS) and overall survival (OS) rates than those with p-mTOR-negative tumors in univariable analyses, and there was a trend toward a correlation between p-mTOR expression and survival in multivariable analyses. RAD001 markedly inhibited dose-dependently proliferation of human gastric carcinoma cells by down-regulating expression of p70s6k, p-p70s6k, C-myc, CyclinD1 and Bcl-2, up-regulating expression of P53.
In gastric cancer, p-mTOR is a potential therapeutic target and RAD001 was a promising treatment agent with inducing cell cycle arrest and apoptosis by down-regulating expression of C-myc, CyclinD1 and Bcl-2, up-regulating expression of P53.